Clinical and Diagnostic Laboratory Immunology, July 1998, p. 561-566, Vol. 5, No. 4
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Assignment of Immunoglobulin G1 and G2
Concentrations to Pneumococcal Capsular Polysaccharides 3, 6B, 14, 19F, and 23F in Pneumococcal Reference Serum 89-SF
Anu
Soininen,1,*
Ilkka
Seppälä,2
Tomi
Wuorimaa,1 and
Helena
Käyhty1
Department of Vaccines, National Public Health Institute
(KTL),1 and
Infection Serology Unit,
Division of Bacteriology and Immunology, HUCH Diagnostics, Helsinki
University Central Hospital,2 Helsinki, Finland
Received 23 December 1997/Returned for modification 26 February
1998/Accepted 22 April 1998
 |
ABSTRACT |
We describe standardization of an enzyme-linked immunosorbent assay
(ELISA) for measuring immunoglobulin G1 (IgG1) and IgG2 concentrations
of antibodies to pneumococcal capsular polysaccharide (Pnc PS). The
ELISA uses a human pneumococcal reference serum pool, lot 89-SF, as a
reference. IgG1 and IgG2 concentrations were assigned to antibodies to
Pnc PS serotypes 3, 6B, 14, 19F, and 23F in 89-SF by ELISA using
affinity-purified monoisotypic IgG1 and IgG2 preparations. The sum of
IgG1 and IgG2 concentrations in 89-SF agrees well with the previously
assigned IgG concentrations. The IgG1 and IgG2 values in 89-SF were
used to measure antibodies to Pnc PS 6B, 14, and 23F in adult pre- and
postimmunization sera and the sum of IgG1 and IgG2 concentrations
correlated well with the IgG values. Furthermore, the IgG2/IgG1 ratio
did not affect the detection of IgG1, the isotype usually represented
by a lower concentration.
 |
INTRODUCTION |
Streptococcus pneumoniae
is an important cause of respiratory infections and serious invasive
diseases (6, 8, 13). It is known that antibodies to capsular
polysaccharides (PS) of pneumococci provide protection against disease,
and pneumococcal vaccines are developed to induce antibodies to PS.
However, PS vaccines are not immunogenic in infants, and thus new
saccharide-protein conjugate vaccines with improved immunogenicity are
under evaluation (11).
Immunoglobulin G (IgG) subclass determinations are important for many
reasons. Vaccination with plain PS such as pneumococcal PS (Pnc PS)
elicits antibodies that are restricted to the rare IgG2 subclass in
humans (3, 7, 22, 27), whereas antibodies to proteins are
predominantly IgG1 (18, 25). Several studies have suggested
that saccharide-protein conjugate vaccines can also induce antibodies
of the IgG1 subclass (15, 23, 24), which is typical for
responses to T-cell-dependent antigens. To study T-cell dependency of
the response to conjugate vaccines, it would thus be informative to
measure subclass responses as well. Furthermore, functional differences
between subclasses (2, 5) and thus determination of IgG
subclasses help to evaluate functional activity of antibodies to
capsular PS. However, several reports show that it is not clear whether
a particular IgG subclass is necessary for defense against encapsulated
bacteria or if all subclasses provide equivalent levels of protection
(12, 14, 28). Moreover, quantification of IgG subclass
concentration is important in the diagnosis of individuals with
specific antibody deficiencies (16).
Standardization of solid-phase methods for determination of subclass
composition of antibodies has been difficult because properly
standardized isotype-specific reagents and a standard serum with
assigned weight-based units of different subclasses have been missing.
IgG subclasses of antibodies measured by solid-phase methods have
usually been expressed as enzyme immunoassay units of test sera at a
specific optical density (OD) as compared to a standard serum. However,
enzyme immunoassay units are not comparable except within well planned
experiments because different subclass-specific second antibodies can
have different affinities for the first antibody, leading to under- or
overestimation of subclasses (25). Several methods have been
used for quantitation of immunoglobulin isotypes, including measurement
of concentrations of isotypes after purification of specific antibody
(26) or measurement of specific antibody after physical
separation of immunoglobulin isotypes (4). Myeloma proteins
attached to plastic surfaces have been used as standards (10, 18,
20), but this method gives erroneously high results because of
partial unavailability of epitopes (17). Moreover, purified
isotype fractions have served as standards in solid-phase methods in
which the affinity differences between different reagents have been
corrected by coefficients (25, 26). Calibration of human
reference sera can also be done by heterologous interpolation of the
specific antibody response with dose-response curves generated with
heterologous engineered human-mouse chimeric antibody (9).
An approach for measuring IgG subclass concentrations of anti-Pnc PS
antibodies by an enzyme-linked immunosorbent assay (ELISA) is presented
here. Comparison of ELISA results could be facilitated by using an
international reference serum. Therefore, determination of anti-Pnc PS
IgG1 and IgG2 antibody concentrations in a pneumococcal reference
serum, lot 89-SF (21), allows interlaboratory
standardization of subclass assays. Furthermore, it allows comparison
of subclasses within a serotype and between serotypes. Finally, the
IgG1 and IgG2 values of anti-Pnc PS 3, 6B, 14, 19F, and 23F present in reference serum 89-SF (21) determined in this study were
used to quantitate IgG1 and IgG2 concentrations of antibodies to Pnc PS
types 6B, 14, and 23F in sera of healthy adults after vaccination with
the 23-valent polysaccharide vaccine or with one of the four conjugate
vaccines. The sum of IgG1 and IgG2 concentrations was compared with the
IgG values determined by a standard IgG ELISA.
 |
MATERIALS AND METHODS |
Sera.
Pneumococcal reference serum lot 89-SF is a pool of
postvaccination adult sera. It was provided by Carl Frasch, CBER, Food and Drug Administration, Bethesda, Md. IgG antibody concentrations to
Pnc PS in the reference serum have been previously described (21).
Adult sera were obtained from 46 healthy adults before and 1 month
after vaccination (27a). Fourteen of them received one dose
of 23-valent polysaccharide vaccine (Merck, Sharp & Dohme, West Point,
Pa.), 10 of them received pentavalent oligosaccharide conjugate PncCRM
(Lederle-Praxis Biologicals, West Henrietta, N.Y.) (1), 10 of them received PnT (PASTEUR-MERIEUX Sérums & Vaccins, Lyon,
France) (19), and 12 of them received PncD (Connaught
Laboratories Inc., Swiftwater, N.Y.) (19). Sera were stored
at
20°C until tested.
Monoclonal antibodies against human IgG subclasses.
Mouse
monoclonal antibodies to human IgG1 (clone HP6070) and IgG2 (clone
HP6002) were purchased from Zymed Laboratories, Inc. (San Francisco,
Calif.). The ascitic fluids containing antibodies to IgG1 (HP6070,
2C7), IgG2 (1E4), IgG3 (2F5), and IgG4 (IC2) were from I. Seppälä (HUCH Diagnostics, Helsinki, Finland).
Separation of IgG subclasses from human IgG by protein
A-Sepharose chromatography.
The separation of IgG subclasses from
human IgG is summarized in Fig. 1. Two
columns (5 mm by 21 cm) of protein A-Sepharose (Pharmacia Fine
Chemicals, Uppsala, Sweden) were set in tandem and washed with 0.1 M
sodium citrate buffer (pH 7.0) overnight. Eighty milligrams of a human
immunoglobulin infusion substance known to contain anti-Pnc PS
antibodies (Sandoglobulin; protein, 96% IgG; Sandoz, Sa Bale,
Switzerland), filtered and neutralized with 1/10 volume of 1 M Tris-HCl
(pH 7.6), was applied. Columns were washed with 0.1 M sodium citrate
buffer (pH 7.0) until the first protein peak had appeared. A linear pH
gradient from 0.1 M sodium citrate (pH 7.0) to 0.1 M sodium citrate (pH
3.0), monitored at 277 nm with high-performance liquid chromatography
equipment (LKB, Bromma, Sweden), was then applied. Fractions were
analyzed for protein content and, after neutralization with 1 M
Tris-HCl (pH 8.3), for the distribution of IgG subclasses by ELISA
(Fig. 2A). A Pnc PS type 6B ELISA was
used for IgG2 and a tetanus toxoid (Tt) ELISA was used for IgG1 because
it is known that anti-Pnc PS 6B antibodies are mainly of the IgG2
subclass and anti-Tt antibodies are mainly of the IgG1 subclass
(3, 7, 21, 24, 26). Fractions with a higher ELISA activity
of IgG1 than of IgG2 (fractions 45 to 48 in Fig. 2A) were pooled for
further purification; this IgG1-enriched preparation was then applied
to an anti-IgG2 column (see below) for fractionation of IgG1 and IgG2.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Steps in purification of monoisotypic IgG1 and IgG2
preparations and determination of IgG1 and IgG2 anti-Pnc PS in
pneumococcal reference serum 89-SF. Those steps marked with a
superscript "a" were followed by determination of IgG1 titer to Tt
and IgG2 titer to Pnc PS 6B (Fig. 2) and subsequent pooling of the
fractions into subclass preparations.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Separation of IgG1 and IgG2 from human IgG by
protein A-Sepharose chromatography. Each fraction was analyzed for
titer of IgG1 antibody to Tt and for titer of IgG2 antibody to Pnc PS
6B. Fractions 45 to 48 were pooled (IgG1-enriched preparation) and
purified further by anti-IgG2 affinity chromatography. (B) Purification
of IgG1 and IgG2 by anti-IgG2 affinity chromatography. Fractions 4 to
19 and 26 to 31 were pooled to create an IgG1 preparation and an IgG2
preparation, respectively.
|
|
Purification of IgG1 and IgG2 preparations by anti-IgG2 affinity
chromatography.
IgG1 and IgG2 preparations were derived from the
IgG1-enriched preparation from protein A-Sepharose chromatography (Fig.
1). A mouse monoclonal antibody specific for an epitope common to human
IgG2 and IgG4 (1E4) was used for affinity purification of IgG1 and IgG2
preparations. A total of 79.7 mg of the ascitic fluid, after
ultracentrifugation at 178,000 × g for 20 min for removal of lipoproteins, was coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia Biotech, Uppsala, Sweden) as described in the
instructions of the manufacturer with a final matrix volume of 1.5 ml.
A volume of 330 µl (protein, 5 mg) of protein A-Sepharose IgG1-enriched preparation was applied to the column. Fall-through fractions containing unbound IgG1 were collected by using
phosphate-buffered saline (PBS). IgG2 was eluted by 0.1 M glycine-HCl
(pH 4.0 to 3.0). Fractions were analyzed for protein content and pH and
neutralized as described above. The purity of IgG1 and IgG2 in the
affinity chromatography fractions (Fig. 2B) was analyzed by ELISA as
described above. The mainly IgG1 and mainly IgG2 fractions were first
pooled to create an IgG1 preparation (fractions 4 to 19) and an IgG2 preparation (fractions 26 to 31), respectively. Then, anti-Pnc PS
antibodies in these preparations were analyzed for monoisotypic purity
by IgG subclass (IgG1 to -4) ELISA (see below).
ELISA for anti-Pnc PS IgG antibodies.
A standard ELISA was
performed as described earlier by Käyhty et al. (11)
with one exception: a different conjugate, an alkaline-phosphate
conjugated anti-human IgG (Sigma Immuno Chemicals, St. Louis, Mo.), was
used.
ELISA for Pnc PS IgG subclass antibodies.
An ELISA specific
for IgG subclasses was a four-layer modification of the ELISA described
earlier by Käyhty et al. (11). Microtiter plates
(MaxiSorp; Nunc, Roskilde, Denmark) were coated with Pnc PS (American
Type Culture Collection, Rockville, Md.) as described earlier
(11). A microtiter plate coated with pneumococcal C-polysaccharide (CPS; Statens Seruminstitut, Copenhagen, Denmark) in
PBS (CPS, 1 µg/ml) was included in each assay to ensure the efficacy
of CPS neutralization. Sera were first diluted 1:100 in 10% fetal
bovine serum in PBS (10% FBS) containing 10 µg of CPS per ml, and,
after 30 min of incubation at room temperature, threefold dilutions
were made. Microtiter plates were incubated sequentially with mouse
monoclonal antibodies to human IgG subclasses for 2 h at 37°C,
with alkaline-phosphatase conjugated rabbit anti-mouse antibody
(Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.) at 22°C
overnight, and with p-nitrophenyl phosphate (Sigma Diagnostics, St. Louis, Mo.) for 30 min at 37°C.
The anti-Pnc PS IgG1 and IgG2 concentrations were calculated by using
the subclass-specific concentrations in the pneumococcal reference
serum 89-SF (Food and Drug Administration, Bethesda, Md.)
(21) determined in this study (Fig. 1). The results are given in micrograms per milliliter. The lower detection limits were
0.08, 0.06, 0.08, 0.20, and 0.06 µg/ml for IgG1 and 0.14, 0.18, 0.26, 0.20, and 0.18 µg/ml for IgG2 in assays of Pnc PS types 3, 6B, 14, 19F, and 23F, respectively. Half the concentration of the lower limit
of detection was used in cases where the concentration remained below
the detection limit. The interassay variation was monitored by running
two in-house control serum samples on every plate. The coefficients of
variance (CV) were 13.5 and 18.1% for PS 3 (n = 8),
13.2 and 11.9% for PS 6B (n = 12), 16.0 and 15.2% for
PS 14 (n = 12), 16.0 and 24.0% for PS 19F
(n = 8), and 15.3 and 20.4% for PS 23F
(n = 11) in the IgG1 and IgG2 assays, respectively.
To analyze the monoisotypic purity of Pnc PS antibodies in the IgG1 and
IgG2 preparations, the IgG and IgG1 to -4 antibody titers to Pnc PS 3, 6B, 14, 19F, and 23F in the preparations were determined in ELISAs
specific for IgG and IgG1 to -4. Serial dilutions starting at 1:2 were
done in 10% FBS containing 20 µg of CPS per ml for all assays. The
end point titers were assigned as a reciprocal of the dilution that
gave an OD of 0.3.
ELISA for Tt IgG1 antibodies.
Because IgG1 is a minor
isotype in PS antibodies and is the predominant isotype in antibodies
to proteins, we monitored the success in purifying the IgG1 fraction in
chromatography by a Tt-specific ELISA. Tt (National Public Health
Institute, Helsinki, Finland) in PBS (15 lf [limit of
flocculation]/ml) was used for coating microtiter plates (Greiner,
Frickenhausen, Germany) by incubation for 2 h at 37 or 4°C
overnight. After six washes with saline plus 0.02% Tween 20 and 0.9%
NaCl, samples diluted in 10% FBS were added to microtiter plates. The
samples were incubated for 2 h at room temperature, after which
the plates were washed as described above. Mouse anti-human IgG1
(HP6070) was diluted in 10% FBS and incubated for 1 h at room
temperature. The plates were washed as described above, a substrate,
4-nitrophenylphosphate (1 mg/ml) in 0.02 M diethanolamine buffer (pH
10.0), containing 1 mM MgCl2, was added, and the plates
were incubated for 30 min. The A405 was measured
by an ELISA reader (Multiscan; Labsystems, Helsinki, Finland).
Statistical methods.
The correlation coefficients were
calculated with the Excel 7.0 program by using log-transformed
data.
 |
RESULTS AND DISCUSSION |
Isotypic purity of the IgG1 and IgG2 preparations.
The aim of
this study was to determine IgG1 and IgG2 concentrations of antibodies
to pneumococcal serotypes in the internationally used pneumococcal
reference serum pool lot 89-SF (21). In our approach, an IgG
preparation known to contain antibodies to Pnc PS was fractionated into
IgG1 and IgG2 preparations and then Pnc PS antibodies were determined
(Fig. 1). The IgG1 and the IgG2 preparations were therefore run in
ELISAs specific for IgG, IgG1, IgG2, IgG3, and IgG4 antibodies to Pnc
PS types 3, 6B, 14, 19F, and 23F. To estimate the monoisotypic purity
of the preparations, we compared titers of IgG1, IgG2, IgG3, and IgG4.
Because different second antibodies can have different affinities and
thus the titers of different subclasses cannot be directly compared, we
used correction coefficients to correct the bias. The corrected titers
obtained this way (Table 1) are
comparable to each other regardless of the subclass because they are
relative to the IgG reagent. The IgG and IgG1 to -4 curves and
determination of the titers are illustrated in Fig.
3. The curve of the specific subclass
titers was usually nearly identical to the curve of IgG titers. When the IgG1 preparation was titrated with anti-IgG and anti-IgG1 to -IgG4
antibodies, it was found that the titer of IgG1 was 1.25 times higher
than the titer of IgG (mean of IgG1 determinations, all serotypes) and
thus the IgG1 second antibody was 1.25 times more efficient in binding
the first antibody than the IgG second antibody was. The titer of IgG1
(data not shown) was then divided by 1.25, the coefficient, to obtain
the corrected titer (Table 1). It was easy to calculate the coefficient
for IgG1 because no contaminating IgG2 to IgG4 antibodies were detected
in the IgG1 preparation. Only antibodies to PS 19F had contaminating IgG4 with a low titer of 1. Because IgG4 did not yet have a
coefficient, we made an assumption that the coefficient for IgG4 was 1. A titer of 1 for IgG4 obtained in this way had to be subtracted from
the titer of anti-PS 19F IgG before calculation of the IgG1/IgG ratio. Thereafter, the coefficient for IgG2 was calculated. Because the IgG2
preparation was less pure than the IgG1 preparation, the IgG1, IgG3,
and IgG4 titers had to be subtracted from the titer of IgG before
calculation of the IgG2/IgG ratio. The correction coefficient for the
IgG2 antibody was calculated to be 0.76 (mean of IgG2 determinations,
all serotypes). A coefficient of 0.76 was then used to convert the
titer of IgG2 (data not shown) to a corrected titer (Table 1). This
calculation was based on the assumption that the coefficients for IgG3
and IgG4 were 1. In previous studies (23, 25), a higher
detection efficiency was found for the IgG3 and IgG4 reagents than for
the IgG1 reagent. This implies that the contamination by IgG3 or IgG4
antibodies cannot be seriously underestimated; more likely, it is
slightly overestimated. The IgG1 and IgG2 data do not lose their
validity because of this small uncertainty. After summing up the
corrected titers of all subclasses, we found the mean contamination to
be 3% in the IgG1 preparation and 10% in the IgG2 preparation (Table 1). Based on this, we conclude that these preparations were pure enough
to be used with good accuracy as monoisotypic references.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Corrected titers of IgG1, IgG2, IgG3, and IgG4 and sum of
the titers of IgG1 to -4 antibodies to Pnc PS 3, 6B, 14, 19F, and 23F
in the affinity-purified IgG1 and
IgG2 preparationsa
|
|

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
Titration of IgG and IgG1 to -4 antibodies in the IgG1
and IgG2 preparations to Pnc PSs 3, 6B, 14, 19F, and 23F. To calculate
the correction coefficients for subclass-specific second antibodies,
the end point titers of IgG and IgG1 to -4 were assigned as a
reciprocal of the dilution that gave an OD of 0.3.
|
|
Assignment of IgG1 and IgG2 concentrations of Pnc PS antibodies to
the reference serum 89-SF.
The monoisotypic preparations were then
used as references in an ELISA to assign IgG1 and IgG2 concentrations
of Pnc PS-specific antibodies in reference serum 89-SF. First, a
standard ELISA was used in three or four separate experiments to
measure the IgG concentration of antibodies to Pnc PS 3, 6B, 14, 19F,
and 23F in the affinity-purified IgG1 and IgG2 preparations, and the
mean values were equated with concentrations of IgG1 and IgG2 anti-Pnc PS present in the monoisotypic IgG1 and IgG2 preparations,
respectively. Second, because of the limited supply of the IgG1 and
IgG2 preparations, they were used as references in an IgG
subclass-specific ELISA to determine the IgG1 and IgG2 Pnc PS
concentrations in reference serum 89-SF (21). Again, each
test was run at least three times and the means were assigned as the
IgG subclass-specific concentrations (Table
2). CV for values assigned on different
days usually remained below 20% (n = 3 to 4). The sum
of IgG1 and IgG2 concentrations was consistent with the previously
determined (21) IgG concentration to the same serotype and
was 66 to 91% of the IgG concentration to serotypes 3, 6B, 14, 19F,
and 23F (Table 2). Moreover, the IgG concentration determined earlier
(21) may also contain IgG3 and IgG4 antibodies to Pnc PS
that were not measured in the present study. The now-assigned
values of IgG1 and IgG2 for antibodies to Pnc PS in reference serum
89-SF agree well with the previously assigned IgG values
(21), which indicates that the IgG1 and IgG2 values for
89-SF have been reliably determined.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
IgG1 and IgG2 antibody concentrations specific for Pnc PS
3, 6B, 14, 19F, and 23F in the pneumococcal reference serum lot
89-SF as determined by ELISA
|
|
Comparison of the IgG subclass-specific assay to the IgG-specific
assay.
Adult pre- and postimmunization sera (27a) were
quantitated for anti-Pnc PS 6B, 14, and 23F IgG1 and IgG2
concentrations by the IgG subclass-specific ELISA using the
pneumococcal reference serum 89-SF as a reference with the anti-Pnc PS
IgG1 and IgG2 values determined in this study (Table 2). The same sera
were quantitated for IgG concentration by a standard ELISA using the pneumococcal serum pool 89-SF as a reference with the anti-Pnc PS IgG
values determined earlier (21). The correlation between independently determined IgG concentrations and the sum of IgG1 and IgG2 concentrations measured by the IgG
subclass-specific ELISA was determined. Correlation coefficients
were 0.75, 0.84, and 0.80 for the preimmunization sera
(n = 46) and 0.94, 0.96, and 0.95 for the
postimmunization sera (n = 46) for anti-Pnc PS 6B,
14, and 23F, respectively (Fig. 4).
Furthermore, a good correlation was observed for both
IgG1-predominating (IgG2/IgG1,
1) and IgG2-predominating (IgG2/IgG1,
>1) sera (r = 0.96, n = 19 and
r = 0.93, n = 257, respectively; all
serotypes together) when both all prevaccination and all
postvaccination sera were combined. This suggests that there is no bias
between the IgG assay and the IgG subclass assay and furthermore
confirms that the IgG1 and IgG2 concentrations determined for 89-SF
were reliably assigned.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Comparison of the sum of IgG1 and IgG2 concentrations
determined by the IgG subclass ELISA with IgG concentrations of
antibodies to Pnc PS 6B, 14, and 23F in adult pre- and postvaccination
sera (all serotypes combined; n = 46 for each
serotype).
|
|
Isotypic competition for binding to antigen.
We wanted to
determine whether competition for antigen binding sites between IgG
subclasses affects the isotype-specific results. The effect of excess
IgG2 on the measurement of IgG1, the minor subclass in anti-PS IgG
antibodies, was analyzed by mixing various amounts of an adult serum
containing 22.77 µg of IgG2 antibodies and 0.04 µg of IgG1
antibodies, each per ml, to Pnc PS 14 (IgG2-predominating serum) and an
adult serum containing 5.28 µg of IgG2 antibodies and 14.04 µg of
IgG1 antibodies, each per ml, to Pnc PS 14 (IgG1-predominating serum)
to produce the different IgG2/IgG1 ratios described in Table
3. Similar experiments were also
performed with anti-Pnc PS IgG1- and IgG2-predominating sera for
antigens 6B, 19F, and 23F. Suitable anti-Pnc PS 3-containing sera were
not available. No inhibition of IgG1 binding to the antigen by IgG2 was
found. Sera having an IgG2/IgG1 ratio between approximately 10 (range, 9.5 to 10.3) and 100 (range, 98.1 to 100.5) gave identical results in
the IgG subclass ELISA specific for IgG1 (Table 3). As a result, the
IgG subclass ELISA is not affected by competition for antigen binding
sites between IgG subclasses, probably because PS antigens contain
repetitive epitopes that offer multiple binding sites for antibodies.
Therefore, values for IgG1, a rare subclass in antibodies to PS, were
not underestimated.
In conclusion, we have determined the IgG1 and IgG2 anti-Pnc PS
concentrations in the pneumococcal reference serum. The standardized IgG subclass-specific ELISA correlated well with the standard IgG ELISA
for the respective Pnc PS. These determinations can be used to measure
IgG subclass concentrations of antibodies to Pnc PS.
 |
ACKNOWLEDGMENTS |
We thank Arja Vuorela, Hannele Lehtonen, Merja Anttila, and Leena
Saarinen for excellent technical assistance and Pirjo Helena Mäkelä and Juhani Eskola for their helpful discussions
during the writing of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: National Public
Health Institute, Department of Vaccines, Laboratory of Vaccine
Immunology, Mannerheimintie 166, 00300 Helsinki, Finland. Phone:
358-9-4744 8587. Fax: 358-9-4744 8599. E-mail:
anu.soininen{at}ktl.fi.
 |
REFERENCES |
| 1.
|
Åhman, H.,
H. Käyhty,
P. Tamminen,
A. Vuorela,
F. Malinkoski, and J. Eskola.
1996.
Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants.
Pediatr. Infect. Dis. J.
15:134-139[Medline].
|
| 2.
|
Amir, J.,
M. G. Scott,
M. H. Nahm, and D. M. Granoff.
1990.
Bactericidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to Haemophilus influenzae type b.
J. Infect. Dis.
162:163-171[Medline].
|
| 3.
|
Barrett, D. J., and E. M. Ayoub.
1986.
IgG2 subclass restriction of antibody to pneumococcal polysaccharides.
Clin. Exp. Immunol.
63:127-134[Medline].
|
| 4.
|
Bird, P.,
J. Lowe,
R. P. Stokes,
A. G. Bird,
N. R. Ling, and R. Jefferis.
1984.
The separation of human serum IgG into subclass fractions by immunoaffinity chromatography and assessment of specific antibody activity.
J. Immunol. Methods
71:97-105[Medline].
|
| 5.
|
Bredius, R. G. M.,
P. C. Driedijk,
M. F. J. Schouten,
R. S. Weening, and T. A. Out.
1992.
Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.
Infect. Immun.
60:4838-4847[Abstract/Free Full Text].
|
| 6.
|
Eskola, J.,
A. Takala,
E. Kela,
E. Pekkanen,
R. Kalliokoski, and M. Leinonen.
1992.
Epidemiology of invasive pneumococcal infections in children in Finland.
JAMA
68:3323-3327.
|
| 7.
|
Freijd, A.,
L. Hammarström,
M. A. A. Persson, and C. I. E. Smith.
1984.
Plasma anti-pneumococcal antibody activity of the IgG class and subclasses in otitis prone children.
Clin. Exp. Immunol.
56:233-238[Medline].
|
| 8.
|
Gray, B. M.,
G. M. Converse, and H. C. Dillon.
1980.
Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life.
J. Infect. Dis.
142:923-933[Medline].
|
| 9.
|
Hamilton, R. G.
1990.
Application of engineered chimeric antibodies to the calibration of human antibody standards.
Ann. Biol. Clin.
49:242-248.
|
| 10.
|
Hammarström, L.,
M. Granström,
V. Oxelius,
M. A. A. Persson, and C. I. E. Smith.
1984.
IgG subclass distribution of antibodies against S. aureus teichoic acid and -toxin in normal and immunodeficient donors.
Clin. Exp. Immunol.
55:593-601[Medline].
|
| 11.
|
Käyhty, H.,
H. Åhman,
R.-R. Rönnberg,
R. Tiilikainen, and J. Eskola.
1995.
Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children.
J. Infect. Dis.
172:1273-1278[Medline].
|
| 12.
|
Käyhty, H.,
O. Mäkelä,
J. Eskola,
L. Saarinen, and I. Seppälä.
1988.
Isotype distribution and bactericidal activity of antibodies after immunization with Haemophilus influenzae type b vaccines at 18-24 months of age.
J. Infect. Dis.
158:973-982[Medline].
|
| 13.
|
Klein, J. O.
1990.
The epidemiology of pneumococcal disease in infants and children.
Rev. Infect. Dis.
162:1316-1323.
|
| 14.
|
Lortan, J.,
A. Kaniuk, and M. Monteil.
1993.
Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults.
Clin. Exp. Immunol.
91:54-57[Medline].
|
| 15.
|
Mäkelä, O.,
F. Péterfy,
I. G. Outschoorn,
A. W. Richter, and I. Seppälä.
1984.
Immunogenic properties of (1 6) dextran, its protein conjugates, and conjugates of its breakdown products in mice.
Scand. J. Immunol.
19:541-550[Medline].
|
| 16.
|
Matter, L.,
J. A. Wilhelm,
W. Angehrn,
F. Skvaril, and K. Schopfer.
1985.
Selective antibody deficiency and recurrent pneumococcal bacteremia in a patient with Sjögren's syndrome, hyperimmunoglobulinemia G, and deficiencies of IgG2 and IgG4.
N. Engl. J. Med.
312:1039-1042[Medline].
|
| 17.
|
Mattila, P. S.
1985.
Quantitation of antibody isotypes in solid-phase assays. Comparison of myeloma protein and monoisotypic antibody standards.
J. Immunol. Methods
83:43-53[Medline].
|
| 18.
|
Morell, A.,
B. Roth-Wicky, and F. Skvaril.
1983.
Immunoglobulin G subclass restriction of antibodies against hepatitis B surface antigen.
Infect. Immun.
39:565-568[Abstract/Free Full Text].
|
| 19.
|
Nieminen, T.,
J. Eskola, and H. Käyhty.
1998.
Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum.
Vaccine
16:630-636[Medline].
|
| 20.
|
Persson, M. A. A.,
L. Hammarström, and C. I. E. Smith.
1985.
Enzyme-linked immunosorbent assay for subclass distribution of human IgG and IgA antigen-specific antibodies.
J. Immunol. Methods
78:109-121[Medline].
|
| 21.
|
Quataert, S. A.,
C. S. Kirch,
L. J. Quackenbush Wiedl,
D. C. Phipps,
S. Strohmeyer,
C. O. Cimino,
J. Skuse, and D. C. Madore.
1995.
Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S.
Clin. Diagn. Lab. Immunol.
2:590-597[Abstract].
|
| 22.
|
Sarvas, H.,
N. Rautonen,
S. Sipinen, and O. Mäkelä.
1989.
IgG subclasses of pneumococcal antibodies effect of allotype G2m(n).
Scand. J. Immunol.
29:229-237[Medline].
|
| 23.
|
Seppälä, I.,
H. Sarvas,
O. Mäkelä,
P. Mattila,
J. Eskola, and H. Käyhty.
1988.
Human antibody responses to two conjugate vaccines of Haemophilus influenzae type b saccharides and diphtheria toxin.
Scand. J. Immunol.
28:471-479[Medline].
|
| 24.
|
Seppälä, I.,
J. Pelkonen, and O. Mäkelä.
1985.
Isotypes of antibodies by plain dextran or a dextran-protein conjugate.
Eur. J. Immunol.
15:827-833[Medline].
|
| 25.
|
Seppälä, I. J. T.,
N. Routonen,
A. Sarnesto,
P. A. Mattila, and O. Mäkelä.
1984.
The percentages of six immunoglobulin isotypes in human antibodies to tetanus toxoid: standardization of isotype-specific second antibodies in solid-phase assay.
Eur. J. Immunol.
14:868-875[Medline].
|
| 26.
|
Shackelford, P. G.,
D. M. Granoff,
S. J. Nelson,
M. G. Scott,
D. S. Smith, and M. H. Nahm.
1987.
Subclass distribution of human antibodies to Haemophilus influenzae type b capsular polysaccharide.
J. Immunol.
138:587-592[Abstract].
|
| 27.
|
Siber, G. R.,
P. H. Schur,
A. C. Aisenberb,
S. A. Weitzman, and G. Schiffman.
1980.
Correlation between serum IgG2 concentrations and the antibody response to bacterial polysaccharide antigens.
N. Engl. J. Med.
303:178-182[Abstract].
|
| 27a.
| Soininen, A., et al. Submitted for publication.
|
| 28.
|
Weinberg, G.,
D. Granoff,
M. Nahm, and P. Shackelford.
1986.
Functional activity of different IgG subclass antibodies against type b capsular polysaccharide of Haemophilus influenzae.
J. Immunol.
136:4232-4236[Abstract].
|
Clinical and Diagnostic Laboratory Immunology, July 1998, p. 561-566, Vol. 5, No. 4
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.